Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials.

@article{Wilcock2008AntiamyloidbetaII,
  title={Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials.},
  author={Donna M Wilcock and Carol A. Colton},
  journal={Journal of Alzheimer's disease : JAD},
  year={2008},
  volume={15 4},
  pages={
          555-69
        }
}
Therapeutic approaches to the treatment of Alzheimer's disease are focused primarily on the amyloid-beta peptide which aggregates to form amyloid deposits in the brain. The amyloid hypothesis states that amyloid is the precipitating factor that results in the other pathologies of Alzheimer's disease. One such therapy that has attracted significant attention is anti-amyloid-beta immunotherapy. First described in 1999, immunotherapy uses anti-amyloid-beta antibodies to lower brain amyloid levels… CONTINUE READING

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 38 CITATIONS

Active immunization therapies for Parkinson's disease and multiple system atrophy.

  • Movement disorders : official journal of the Movement Disorder Society
  • 2016
VIEW 1 EXCERPT
CITES RESULTS

Amyloid-β immunization enhances neurogenesis and cognitive ability in neonatal mice.

  • International journal of clinical and experimental medicine
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND